N-acetyl-ε-aminocapramide | 2827-32-9

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: N-acetyl-ε-aminocapramide
• 英文别名: 6-acetamidohexanoamide；6-Acetylaminohexansaeureamid；6-Acetamino-hexansaeureamid；6-Acetamidohexanamide
• CAS: 2827-32-9
• 化学式: C₈H₁₆N₂O₂
• mdl: MFCD00012108
• 分子量: 172.227
• InChiKey: DKTLRYBPEORJBF-UHFFFAOYSA-N

物化性质

• 熔点：
  115-116 °C
• 沸点：
  457.9±28.0 °C(Predicted)
• 密度：
  1.029±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.5
• 重原子数：
  12
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  72.2
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  己内酰胺 、 乙酰胺 反应 11.0h， 以42%的产率得到N-acetyl-ε-aminocapramide
  参考文献：
  名称：

  Spasskaya, R. I.; Zil'berman, E. N.; Radina, I. A., Journal of Organic Chemistry USSR (English Translation), 1982, vol. 18, # 10, p. 1809 - 1812

  摘要：

  DOI：

文献信息

• [EN] 3-(4-AMIDOPYRROL-2-YLMETHLIDENE)-2-INDOLINONE DERIVATIVES AS MULTI-TARGET PROTEIN KINASE INHIBITORS AND HISTONE DEACETYLASE INHIBITORS<br/>[FR] DÉRIVÉS DE 3-(4-AMIDOPYRROL-2-YLMÉTHYLIDÈNE)-2-INDOLINONE COMME INHIBITEURS DE PROTÉINE KINASE ET INHIBITEURS D'HISTONE DÉSACÉTYLASE MULTI-CIBLES
  申请人：SHENZEN CHIPSCREEN BIOSCIENCE

  公开号：WO2009014941A1

  公开（公告）日：2009-01-29

  Isolated compounds of formula (I): and stereoisomers, enantiomers, diastereomers, and pharmaceutically acceptable salts thereof are described, as well as processes for production, and methods of use of these compounds and compositions thereof for the treatment of diseases associated with abnormal protein kinase activities and/or abnormal histone deacetylase activities including, for example, inflammatory diseases, autoimmune diseases, cancer, amelioration of abnormal cell proliferation, neurological and neurodegenerative diseases, cardiovascular diseases, allergies and asthma and/or hormone-related diseases.

  公式（I）的孤立化合物及其立体异构体、对映体、二对映体和药学上可接受的盐已被描述，以及用于治疗与异常蛋白激酶活性和/或异常组蛋白去乙酰化酶活性相关的疾病的这些化合物和其组合物的生产过程和使用方法，例如炎症性疾病、自身免疫疾病、癌症、改善异常细胞增殖、神经和神经退行性疾病、心血管疾病、过敏和哮喘和/或激素相关疾病。
• Proteasome inhibitors and methods of using the same
  申请人：Bernadini Raffaella

  公开号：US20050107307A1

  公开（公告）日：2005-05-19

  The present invention provides boronic acid compounds, boronic esters, and compositions thereof that can modulate apoptosis such as by inhibition of proteasome activity. The compounds and compositions can be used in methods of inducing apoptosis and treating diseases such as cancer and other disorders associated directly of indirectly with proteasome activity.

  本发明提供了硼酸化合物、硼酸酯及其组合物，可以通过抑制蛋白酶体活性等方式调节细胞凋亡。这些化合物和组合物可以用于诱导细胞凋亡并治疗癌症等疾病，以及与蛋白酶体活性直接或间接相关的其他疾病。
• PROTEASOME INHIBITORS AND METHODS OF USING THE SAME
  申请人：Bernardini Raffaella

  公开号：US20090291918A1

  公开（公告）日：2009-11-26

  The present invention provides boronic acid compounds, boronic esters, and compositions thereof that can modulate apoptosis such as by inhibition of proteasome activity. The compounds and compositions can be used in methods of inducing apoptosis and treating diseases such as cancer and other disorders associated directly of indirectly with proteasome activity.

  本发明提供了硼酸化合物、硼酸酯及其组合物，可以调节细胞凋亡，例如通过抑制蛋白酶体活性。这些化合物和组合物可以用于诱导细胞凋亡和治疗癌症及其他与蛋白酶体活性直接或间接相关的疾病。
• Proteasome Inhibitors and Methods of Using the Same
  申请人：Bernardini Raffaella

  公开号：US20120041196A1

  公开（公告）日：2012-02-16

  The present invention provides boronic acid compounds, boronic esters, and compositions thereof that can modulate apoptosis such as by inhibition of proteasome activity. The compounds and compositions can be used in methods of inducing apoptosis and treating diseases such as cancer and other disorders associated directly of indirectly with proteasome activity.

  本发明提供了硼酸化合物、硼酸酯及其组合物，可以调节凋亡，例如通过抑制蛋白酶体活性。这些化合物和组合物可以用于诱导凋亡和治疗癌症以及其他与蛋白酶体活性直接或间接相关的疾病的方法。
• Proteasome Inhibitors And Methods Of Using The Same
  申请人：Cephalon, Inc.

  公开号：US20140088042A1

  公开（公告）日：2014-03-27

  The present invention provides boronic acid compounds, boronic esters, and compositions thereof that can modulate apoptosis such as by inhibition of proteasome activity. The compounds and compositions can be used in methods of inducing apoptosis and treating diseases such as cancer and other disorders associated directly of indirectly with proteasome activity.

  本发明提供了硼酸化合物、硼酸酯及其组合物，可以调节凋亡，例如通过抑制蛋白酶体活性。这些化合物和组合物可以用于诱导凋亡和治疗癌症和其他与蛋白酶体活性直接或间接相关的疾病的方法。